Back to overview

DNA Test

Table of Contents

What DNA testing actually tells you
Ancestry testing: patterns, not borders
Pharmacogenomics: where DNA testing delivers
Health risk predictions: proceed with caution
Privacy considerations
Carrier screening: actionable information for family planning

What DNA testing actually tells you

Direct-to-consumer DNA testing has grown into a multi-billion dollar industry, promising insights into ancestry, disease risk, and personalized wellness. The reality is more nuanced. Genetic tests identify variations in your DNA sequence, called single nucleotide polymorphisms (SNPs), that correlate with certain traits or health conditions. But correlation does not equal destiny. Environment, lifestyle, and epigenetic factors play equally important roles in determining outcomes.

The most reliable genetic insights involve monogenic conditions, where a single mutation directly causes disease. Cystic fibrosis, sickle cell anemia, and Huntington's disease fall into this category. For complex traits like type 2 diabetes, cardiovascular disease, or cognitive decline, dozens or hundreds of genetic variants each contribute small effects. Predicting individual risk from these polygenic scores remains imprecise, with studies showing limited clinical utility beyond traditional risk factors ^[1].

Ancestry testing: patterns, not borders

Ancestry testing compares your DNA to reference populations from different geographic regions. These estimates reflect statistical patterns of genetic similarity rather than definitive national origins. As databases expand and algorithms improve, ancestry reports change. Your results may shift significantly as companies refine their reference panels and statistical models ^[4].

DNA cannot tell you you're "30% French" in any meaningful cultural or national sense. It reveals that you share genetic markers with reference populations from particular regions. Migration, conquest, and trade have mixed human populations for millennia. Genetic clusters rarely align neatly with modern political borders or cultural identities.

Pharmacogenomics: where DNA testing delivers

Pharmacogenomic testing analyzes how genetic variants affect drug metabolism. Variants in cytochrome P450 (CYP) enzymes determine whether you process medications quickly, slowly, or not at all. This information helps physicians select appropriate drugs and doses, reducing adverse reactions and improving efficacy ^[2].

Specific examples demonstrate clear clinical value. CYP2C19 variants affect clopidogrel effectiveness for heart patients. CYP2D6 variants influence codeine metabolism and opioid response. TPMT variants predict thiopurine toxicity in cancer and autoimmune treatments. Guidelines from the Clinical Pharmacogenetics Implementation Consortium now recommend genetic testing before prescribing these medications.

Health risk predictions: proceed with caution

Many direct-to-consumer tests provide disease risk scores based on genome-wide association studies. These reports estimate your statistical likelihood of developing conditions like Alzheimer's, Parkinson's, or certain cancers compared to population averages. The information can empower lifestyle changes or prompt earlier screening. It can also cause unnecessary anxiety when risks are misinterpreted or overstated.

For most complex diseases, genetic risk scores add modest predictive value beyond age, family history, and lifestyle factors. A 2023 systematic review found that polygenic risk scores for cardiovascular disease improved risk prediction only marginally when added to conventional clinical assessments ^[1]. The incremental benefit varies significantly across populations, with most research historically conducted in European ancestry groups.

Privacy considerations

Your genetic data is uniquely identifiable and immutable. Unlike a credit card number, you cannot change your DNA if a database is breached. Direct-to-consumer testing companies have faced scrutiny over data sharing practices, law enforcement access, and potential discrimination ^[3].

Regulatory protections vary by jurisdiction. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurance and employment discrimination based on genetic information. However, GINA does not cover life insurance, disability insurance, or long-term care insurance. Some states have enacted additional protections; others have not. The ethical, legal, and social implications of widespread genetic testing continue to evolve as technology advances ^[5].

Carrier screening: actionable information for family planning

Carrier screening identifies whether you carry recessive genetic variants that could cause disease in offspring if both parents carry the same variant. Conditions like cystic fibrosis, spinal muscular atrophy, and Tay-Sachs disease follow this inheritance pattern. Testing provides actionable information for family planning decisions.

Professional guidelines now recommend offering carrier screening for certain conditions to all couples planning pregnancy, regardless of ethnicity. Expanded carrier screening panels test for hundreds of conditions simultaneously. This approach identifies more at-risk couples but also generates more variants of uncertain significance that require genetic counseling to interpret properly.

References

Share pharmacogenomic results with your doctor

Genetic variants affecting drug metabolism have immediate clinical value. Bring your pharmacogenomic report to medical appointments. It helps physicians select medications and doses that work with your biology, not against it.

Treat risk scores as probabilities, not certainties

A 1.5x risk for a condition with 10% baseline prevalence means your risk is 15%, not 100%. Genetic predisposition loads the gun, but lifestyle often pulls the trigger. Focus on modifiable factors you can control.

Enable two-factor authentication on testing accounts

Genetic data breaches have occurred. Protect your accounts with strong passwords and two-factor authentication. Review privacy settings regularly and understand what data the company retains even if you delete your account.

Consider family implications before testing

Your DNA reveals information about parents, siblings, and children. Test results might uncover unexpected family relationships or health risks that affect relatives. Consider discussing testing decisions with family members when appropriate.

Polygenic scores are improving but imperfect

Current polygenic risk scores explain only 10-20% of disease heritability for most conditions. They become more accurate with larger, more diverse datasets. Treat them as probabilistic guides, not definitive predictions.

pubmed.ncbi.nlm.nih.gov

Ask about pharmacogenomic testing before starting new medications

CPIC guidelines now cover over 20 genes and 80+ drugs. Testing before starting medications like antidepressants, blood thinners, or chemotherapy can prevent adverse reactions and optimize dosing from day one.

pubmed.ncbi.nlm.nih.gov

Consider carrier screening before pregnancy

Both partners should consider expanded carrier screening before conception. If both carry the same recessive variant, you have a 25% chance of having an affected child with each pregnancy.

Review privacy policies before choosing a testing company

Your genetic data cannot be changed like a password. Read the privacy policy carefully to understand how your data will be stored, shared, and protected. Consider companies that allow you to delete your data.

Interpret polygenic risk scores with caution

Risk scores for complex conditions like diabetes or heart disease add limited predictive value beyond traditional factors. Focus on modifiable lifestyle factors rather than genetic determinism.

How accurate are ancestry DNA tests?

Ancestry estimates reflect genetic similarity to reference populations, not definitive origins. Accuracy varies by region, with better precision for European ancestry than some other populations. Results update as databases expand. Siblings can receive different percentages because they inherit different DNA segments from parents.

Should I share my DNA data with research databases?

Contributing to research advances scientific understanding and can improve risk prediction for everyone. However, de-identified data can sometimes be re-identified. Consider the trade-off between contributing to science and maintaining maximum privacy. You can usually opt out later if you change your mind.

Do different DNA testing companies give different results?

Yes, because each company uses different reference populations, algorithms, and genetic marker panels. Health risk reports vary most significantly. Ancestry estimates generally agree on broad regions but differ on specifics. Raw genetic data is consistent across platforms, but interpretation differs.

Can DNA tests predict my risk of getting cancer?

Some DNA tests can identify variants in genes like BRCA1 and BRCA2 that significantly increase breast, ovarian, and prostate cancer risk. These are high-penetrance mutations with clear clinical implications. However, most cancer risk comes from complex interactions between many genetic variants and environmental factors. Polygenic risk scores for cancer add only modest predictive value and should not replace regular screening or lifestyle interventions.

What is pharmacogenomic testing and should I get it?

Pharmacogenomic testing analyzes how your genes affect drug metabolism. It is most valuable if you take or plan to take medications with known pharmacogenomic associations, such as clopidogrel, warfarin, certain antidepressants, or thiopurines. The Clinical Pharmacogenetics Implementation Consortium provides guidelines for which medications warrant testing. Discuss with your doctor whether testing would benefit your specific medication regimen.

Who can access my genetic data from direct-to-consumer testing?

Access depends on the company's privacy policy and your jurisdiction. In the US, law enforcement can request genetic data with a warrant. Some companies share de-identified data with research partners or pharmaceutical companies. Life insurers may request genetic information in some states. Read privacy policies carefully before testing. Some companies allow you to delete your data; others retain it indefinitely. Consider companies based in jurisdictions with strong genetic privacy laws.

What is carrier screening and when should I do it?

Carrier screening identifies whether you carry recessive genetic variants that could cause disease in your children if your partner also carries the same variant. Both partners should ideally complete screening before conception or early in pregnancy. If both are carriers of the same condition, you have a 25% chance of having an affected child with each pregnancy. Genetic counseling can help interpret results and discuss reproductive options including preimplantation genetic testing or prenatal diagnosis.

Can DNA tests predict disease with certainty?

No, except for monogenic conditions like Huntington's disease where a single mutation causes the illness. For complex diseases like diabetes or heart disease, genetic tests only indicate elevated or reduced risk. Environmental factors, lifestyle choices, and chance play equally important roles in whether disease actually develops.